Latest Hotspot

Boehringer's Zongertinib Shows Promising Results in Previously Treated HER2-Mutated Lung Cancer

13 September 2024
4 min read

Boehringer Ingelheim announces favorable initial findings from the primary analysis of Cohort 1 in the Beamion LUNG-1 study, which examines zongertinib (BI 1810631) in previously treated patients with advanced non-small cell lung cancer (NSCLC) harboring activating HER2 mutations. In this cohort, zongertinib achieved a significant objective response rate and exhibited a generally acceptable safety profile.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By May 2024, a total of 132 patients have received daily doses of zongertinib, either 120 mg (75 patients) or 240 mg (57 patients). The primary endpoint for Cohort 1 (120 mg; 75 patients) was met with an objective response rate (ORR) of 66.7% and a 97.5% confidence interval (CI) of 53.8-77.5%, based on an assessment by a blinded independent central review (BICR) (p<0.0001). Tumor reduction of any degree was seen in 94% of patients across both dosage groups, according to investigator evaluations. The trial included a dose expansion phase aimed at determining the optimal dosage of zongertinib for these patients. 

Participants were randomized into two groups: 120 mg (58 patients) and 240 mg (55 patients). Following an interim futility analysis, the 120 mg dose was chosen for further evaluation in Cohort 1, with 17 additional patients enrolled. In the randomized part of the trial, response rates were 72.4% for the 120 mg group and 78.2% for the 240 mg group, while disease control rates (DCRs) were 95% and 100%, respectively.

Data from Phase Ib, Cohort 1 also indicated initial brain activity results with zongertinib. Among patients with asymptomatic brain metastases, 33% (27 patients on 120 mg) and 40% (25 patients on 240 mg) exhibited confirmed objective responses, achieving DCRs of 74% and 92%, respectively, as assessed by RANO-BM standards through BICR. The central nervous system (CNS) is a frequent site for metastasis in NSCLC and is associated with poor prognosis and diminished quality of life. Up to 30% of NSCLC patients with activating HER2 mutations have brain metastases at diagnosis.

Dr. John Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, who is the study's principal investigator, remarked, "These new results could signify a turning point in treating non-small cell lung cancer patients harboring activating HER2 mutations. Although these mutations are uncommon, they are pivotal drivers in some cases of non-small cell lung cancer, and current therapeutic options are extremely limited. Patients with this cancer type generally have a poor outlook, with around 50% responding to initial treatment and just 20% to second-line therapy."

Zongertinib is an experimental oral HER2 tyrosine kinase inhibitor (TKI) being developed for patients with advanced NSCLC with activating HER2 mutations. It has been engineered to avoid targeting wild-type EGFR, thereby reducing associated toxicities. The global Phase III Beamion LUNG-2 trial is comparing zongertinib with the standard of care as a first-line treatment in patients with advanced NSCLC harboring activating HER2 mutations, and is currently enrolling participants.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 12, 2024, there are 660 investigational drugs for the HER2 targets, including 322 indications, 665 R&D institutions involved, with related clinical trials reaching 3342, and as many as 75993 patents.

Zongertinib is a small molecule drug that targets the HER2 receptor and has shown potential in the treatment of various types of cancer and respiratory diseases. The drug is being developed by Boehringer Ingelheim International GmbH and has reached the highest phase of clinical development, which is Phase 3, both globally and in China.

图形用户界面, 文本, 应用程序

描述已自动生成

Johnson & Johnson's Dual IL-23 Inhibitor Guselkumab Receives FDA Approval for Ulcerative Colitis
Hot Spotlight
6 min read
Johnson & Johnson's Dual IL-23 Inhibitor Guselkumab Receives FDA Approval for Ulcerative Colitis
13 September 2024
On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC).
Read →
Phanes Therapeutics Reveals Initial Patient Treated in PT886 and Chemotherapy Clinical Trial
Latest Hotspot
2 min read
Phanes Therapeutics Reveals Initial Patient Treated in PT886 and Chemotherapy Clinical Trial
13 September 2024
Phanes Therapeutics reported that the first patient has received a dose in the clinical trial of PT886 alongside chemotherapy.
Read →
Dupilumab Achieves Primary and All Key Secondary Endpoints in Phase III Study for Bullous Pemphigoid (BP)
Hot Spotlight
6 min read
Dupilumab Achieves Primary and All Key Secondary Endpoints in Phase III Study for Bullous Pemphigoid (BP)
13 September 2024
On September 11, 2024, Sanofi and Regeneron jointly announced that their pivotal study (ADEPT) of Dupilumab (Dupixent) for the treatment of adult patients with Bullous Pemphigoid (BP).
Read →
Initial Positive Clinical Trial Results for CS-1103: A Novel Treatment for Meth and Fentanyl Overdose
Latest Hotspot
2 min read
Initial Positive Clinical Trial Results for CS-1103: A Novel Treatment for Meth and Fentanyl Overdose
13 September 2024
Clear Scientific Reveals Positive Initial Clinical Trial Results for CS-1103, a Novel Treatment for Meth and Fentanyl Overdose.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.